newsfilter
← Latest News
GlobeNewswire·

Ocugen Provides Business Update with Second Quarter 2026 Financial Results

Conference Call and Webcast Today at 8:30 a.m. ET Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry age-related macular